- Health2Sync, Asia’s leading chronic disease management platform, has secured over $20 million in a Series C funding round, paving the way for a planned public listing on the Taiwan capital markets.
- This capital will fuel strategic growth as Health2Sync prepares for its IPO: expanding into new markets (Japan, South Korea, Australia), developing new disease management programs (weight loss, hypertension, GLP-1), and deepening AI integration.
- This investment reflects strong investor confidence in Health2Sync’s established market leadership, its vision to transform chronic disease management through data-driven solutions, and its strategic path towards a public listing.
TAIPEI, TAIWAN – Media OutReach Newswire – 5 March 2025 – Health2Sync (H2), a leading digital health company specializing in chronic disease management, today announced it has raised over US$20 million in a Series C funding round and earlier extension round. This investment will propel the company’s growth initiatives, including expansion into new markets, development of innovative programs, and preparations for a public listing in Taiwan.
https://www.linkedin.com/company/health2sync/
https://www.facebook.com/Health2Sync
https://www.instagram.com/goodfoodlab_h2s/
The issuer is solely responsible for the content of this announcement.
Health2Sync
Founded in 2013, Health2Sync offers digital solutions to help people manage their health with chronic diseases, pre-diabetes, or weight concerns. The company’s achievements include being the first approved digital therapeutics in Taiwan for its insulin dosage titration software, Insultrate, which it co-developed with Sanofi. The company has also received the title of “NEXT BIG” Startup from the Taiwan National Development Council of Taiwan and has served over 1.4 million users worldwide.
For more information, please visit https://www.health2sync.com/.
